Skip to main content

Advertisement

SpringerLink
Log in

Heterogeneity Analysis of 18F-FDG Uptake in Differentiating Between Metastatic and Inflammatory Lymph Nodes in Adenocarcinoma of the Lung: Comparison with Other Parameters and its Application in a Clinical Setting

  • Original Article
  • Published:
Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

Lymph node (LN) characterization is crucial in determining the stage and treatment decisions in patient with lung cancer. Although 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) has a higher diagnostic accuracy in LN characterization than anatomical imaging, differentiating between metastatic and inflammatory LNs is still challenging because both could show high 18F-FDG uptake. The purpose of this study was to assess if the heterogeneity of the 18F-FDG uptake could help in differentiating between inflammatory and metastatic LNs in lung cancer, and to compare with other parameters.

Methods

A total of 44 patients with adenocarcinoma of the lung, who underwent preoperative 18F-FDG PET/CT without having any previous treatments and were revealed to have 18F-FDG-avid LNs, were enrolled. There were 52 pathology-proven metastatic lymph nodes in 26 subjects. The pathology-proven metastatic LNs were compared with 42 pathology-proven inflammatory/benign LNs in 18 subjects. The coefficient of variation (CV) was used to assess the heterogeneity of 18F-FDG uptake by dividing the standard deviation of standardized uptake value (SUV) by mean SUV. The volume of interest was manually drawn based on the combined CT images of 18F-FDG PET/CT (no threshold is used). Comparisons were made with the maximum standardized uptake values (SUVmax), visual assessment of 18F-FDG uptake, longest diameter, and maximum Hounsfield units (HUmax).

Results

Metastatic lymph nodes tended to have higher CVs than the inflammatory LNs. The mean CV of metastatic LNs (0.30 ± 0.08; range: 0.08–0.55) was higher than that of inflammatory LNs (0.17 + 0.06; range, 0.07–0.32; P < 0.0001). On receiver operating characteristic (ROC) curve analysis, the area under curve was 0.901, and using 0.20 as cut-off value, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were 88.5 %, 76.2 %, 82.2 %, 84.3, and 83.0 % respectively. Accuracy of CV was slightly higher than SUVmax and diameter, but significantly higher than visual assessment and HUmax.

Conclusions

In patients with adenocarcinoma of the lung having no prior treatments, metastatic LNs showed more heterogeneous 18F-FDG uptake than inflammatory LNs. Measuring the CV of the SUV derived from a manual volume of interest (VOI) can be helpful in determining metastatic LN of adenocarcinoma of the lung. Including diagnostic criteria of CV into the diagnostic approach can increase the accuracy of mediastinal node status.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Pieterman RM, Van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter GH, et al. Preoperative staging of non-small cell lung cancer with positron-emission tomography. N Eng J Med. 2000;343:254–61.

    Article  CAS  Google Scholar 

  2. De Leyn P, Vansteenkiste J, Cuypers P, Deneffe G, Van Raemdonck D, Coosemans W, et al. Role of cervical mediastinoscopyin staging of non-small cell lung cancer without enlarged mediastinal lymph nodes on CT scan. Eur J Cardiothorac Surg. 1997;12:706–12.

    Article  PubMed  Google Scholar 

  3. Fischer B, Lassen U, Morten J, Larsen S, Loft A, Bertelsen A, et al. Preoperative staging of lung cancer with combined PET-CT. N Eng J Med. 2009;361:32–9.

    Article  CAS  Google Scholar 

  4. Perigaud C, Bridji B, Roussel JC, Sagan C, Mugniot A, Duveau D, et al. Prospective preoperative mediastinal lymph node staging by integrated positron emission tomography-computerised tomography in patients with non-small-cell lung cancer. Eur J Cardiothorac Surg. 2009;36:731–6.

    Article  PubMed  Google Scholar 

  5. Yang W, Fu Z, Yu J, Yuan S, Zhang B, Li D, et al. Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer. Lung Cancer. 2008;61(1):35–43.

    Article  PubMed  Google Scholar 

  6. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519–30.

    Article  PubMed  CAS  Google Scholar 

  7. Chung JH, Cho KJ, Lee SS, Baek HJ, Park JH, Cheon GJ, et al. Overexpression of Glut1 in lymphoid follicles correlates with false-positive 18F-FDG PET results in lung cancer staging. J Nucl Med. 2004;45:999–1003.

    PubMed  CAS  Google Scholar 

  8. Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N. Active and passive mechanisms of [fluorine-18]fluorodeoxyglucose uptake by proliferating and prenecrotic cancer cells in vivo: A microautoradiographic study. J Nucl Med. 1994;35:1067–75.

    PubMed  CAS  Google Scholar 

  9. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucosein vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972–80.

    PubMed  CAS  Google Scholar 

  10. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Whal RL. Intratumoral distribution of tritiatedfluorodeoxyglucose in breast carcinoma. I. Are inflammatory cells important? J Nucl Med. 1995;36:1854–61.

    PubMed  CAS  Google Scholar 

  11. Avril N, Menzel M, Dose J, Schelling M, Weber W, Jänicke F, et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: Histologic and immunohistochemical tissue analysis. J Nucl Med. 2001;42:9–16.

    PubMed  CAS  Google Scholar 

  12. Higashi K, Anaira CC, Wahl RL. Does FDG uptake measure proliferative activityof human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med. 1993;34:414–9.

    PubMed  CAS  Google Scholar 

  13. Hellwig D, Graeter TP, Ukena D, Groeschel A, Sybrecht GW, Schaefers HJ, et al. 18F-FDG PET for mediastinal staging of lung cancer: Which SUV threshold makes sense? J Nucl Med. 2007;48:1761–6.

    Article  PubMed  Google Scholar 

  14. Kernstine KH, Stanford W, Mullan BF, Rossi NP, Thompson BH, Bushnell DL, et al. PET, CT, and MRI with Combidex for mediastinal staging in non-small cell lung carcinoma. Ann Thorac Surg. 1999;68:1022–8.

    Article  PubMed  CAS  Google Scholar 

  15. Cerfolio RJ, Bryant AS, Ojha B, Eloubeidi M. Improving the inaccuracies of clinical staging of patients with NSCLC: A prospective trial. Ann Thorac Surg. 2005;80:1207–13.

    Article  PubMed  Google Scholar 

  16. Cho YS, Choi JY, Lee KS, Kwon OJ, Shim YM, Lee SJ, et al. FDG PET/CT criteria for diagnosing mediastinal lymph node metastasis in patients with non-small cell lung cancer. J Nucl Med. 2007;48 (Suppl 2):85P.

    Google Scholar 

  17. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441:431–6.

    Article  PubMed  CAS  Google Scholar 

  18. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99.

    Article  PubMed  CAS  Google Scholar 

  19. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.

    Article  PubMed  CAS  Google Scholar 

  20. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: Correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1–8.

    Article  PubMed  CAS  Google Scholar 

  21. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353–64.

    Article  PubMed  CAS  Google Scholar 

  22. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med. 2007;13:1211–8.

    Article  PubMed  CAS  Google Scholar 

  23. Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell. 2004;6:447–58.

    Article  PubMed  CAS  Google Scholar 

  24. Vamesu S. Angiogenesis and tumor grading in primary breast cancer patients: An analysis of 158 needle core biopsies. Rom J Morphol Embryol. 2006;47:251–7.

    PubMed  CAS  Google Scholar 

  25. Groves AM, Shastry M, Rodriguez-Justo M, Malhotra A, Endozo R, Davidson T, et al. 18F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:46–52.

    Article  PubMed  CAS  Google Scholar 

  26. Guo J, Higashi K, Ueda Y, Oguchi M, Takegami T, Toga H, et al. Microvessel density: Correlation with 18F-FDG uptake and prognostic impact in lung adenocarcinomas. J Nucl Med. 2006;47:419–25.

    PubMed  CAS  Google Scholar 

  27. Vakkila J, Lotze MT. Inflammation and necrosis promote tumourgrowth. Nat Rev Immunol. 2004;4:641–8.

    Article  PubMed  CAS  Google Scholar 

  28. Nguyen XC, So Y, Chung JH, Lee WW, Park SY, Kim SE. High correlations between primary tumours and loco-regional metastatic lymph nodes in non-small-cell lung cancer with respect to glucose transporter type 1-mediated 2-deoxy-2-F18-fluoro-D-glucose uptake. Eur J Cancer. 2008;44:692–8.

    Article  PubMed  CAS  Google Scholar 

  29. Takamochi K, Yoshida J, Murakami K, Niho S, Ishii G, Nishimura M, et al. Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients. Lung Cancer. 2005;47:235–42.

    Article  PubMed  Google Scholar 

  30. Van der Valk P, Meijer CJ. The histology of reactive lymph nodes. Am J Surg Pathol. 1987;11:866–82.

    Article  PubMed  Google Scholar 

  31. Scott WJ, Gobar LS, Terry JD, Dewan NA, Sunderland JJ. Mediastinal lymph node staging of non-small-cell lung cancer: A prospective comparison of computed tomography and positron emission tomography. J Thorac Cardiovasc Surg. 1996;111(3):642–8.

    Article  PubMed  CAS  Google Scholar 

  32. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Bogaert J, Maes A, et al. Lymph node staging in non small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymphnode stations from 68 patients. J Clin Oncol. 1998;16:2142–9.

    PubMed  CAS  Google Scholar 

  33. Bryant AS, Cerfolio RJ, Klemm KM, Ojha B. Maximum standard uptake value of mediastinal lymph nodes on integrated FDG-PET-CT predicts pathology in patients with non-small cell lung cancer. Ann Thorac Surg. 2006;82:417–23.

    Article  PubMed  Google Scholar 

  34. Kumar A, Dutta R, Kannan U, Kumar R, Khilnani GC, Gupta SD. Evaluation of mediastinal lymph nodes using 18 F-FDG PET-CT scan and its histopathologic correlation. Ann Thorac Med. 2011;6:11–6.

    Article  PubMed  Google Scholar 

  35. Boiselle PM, Patz EF, Vining DJ, Weissleder R, Shepard JA, McLoud TC. Imaging of mediastinal lymph nodes: CT, MR, and FDG PET. Radiographics. 1998;18:1061–9.

    Article  PubMed  CAS  Google Scholar 

  36. Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza E, et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 Suppl):178S–201S.

    Article  PubMed  Google Scholar 

  37. Shim SS, Lee KS, Kim BT, Chung MJ, Lee EJ, Han J, et al. Non-small cell lung cancer: Prospective comparison of integrated FDG PET/CTand CT alone for preoperative staging. Radiology. 2005;236:1011–9.

    Article  PubMed  Google Scholar 

  38. Kim SK, Shin JE, Lee JH. Peripheral tuberculous lymphadenitis masquerading as metastatic gastric carcinoma on F-18 FDG dual time point PET/CT. Nucl Med Mol Imaging. 2012;46:316–7.

    Article  Google Scholar 

  39. Kim YK, Lee KS, Kim BT, Choi JY, Kim H, Kwon OJ, et al. Mediastinal nodal staging of non small cell lung cancer using integrated FDG PET/CT in a tuberculosis-endemic country. Cancer. 2007;109:1068–77.

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Seoul National University Hospital, Seoul, Korea

    Hendra Budiawan, Gi Jeong Cheon, Hyung-Jun Im, Soo Jin Lee, Jin Chul Paeng, Keon Wook Kang, June-Key Chung & Dong Soo Lee

  2. Department of Nuclear Medicine, Mochtar Riady Comprehensive Cancer Centre, Siloam Hospitals Semanggi, Jakarta, Indonesia

    Hendra Budiawan

  3. Cancer Research Institute, Seoul National University, Seoul, Korea

    Gi Jeong Cheon & Keon Wook Kang

  4. Department of Nuclear Medicine, Seoul National University College of Medicine, 101 Daehangro, Jongro-gu, Seoul, 110-744, Korea

    Gi Jeong Cheon

Authors
  1. Hendra Budiawan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gi Jeong Cheon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hyung-Jun Im
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Soo Jin Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jin Chul Paeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Keon Wook Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. June-Key Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Dong Soo Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gi Jeong Cheon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Budiawan, H., Cheon, G.J., Im, HJ. et al. Heterogeneity Analysis of 18F-FDG Uptake in Differentiating Between Metastatic and Inflammatory Lymph Nodes in Adenocarcinoma of the Lung: Comparison with Other Parameters and its Application in a Clinical Setting. Nucl Med Mol Imaging 47, 232–241 (2013). https://doi.org/10.1007/s13139-013-0216-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13139-013-0216-6

Keywords

Search

Navigation